Juvisé Pharmaceuticals has completed a €550m refinancing transaction led by Hayfin Capital Management, strengthening the company’s balance sheet and providing additional capital to support future acquisitions.

The refinancing comprises €400m of existing debt and a new €150m capital expenditure facility earmarked for potential M&A opportunities. Juvisé said the transaction extends its debt maturity profile and improves financial flexibility as the company continues to integrate and expand its portfolio of essential medicines.

Hayfin Capital Management, a European alternative asset management platform with a healthcare focus, led the refinancing. Financial terms beyond the total amount were not disclosed.

The transaction follows Juvisé’s capital opening in 2024, when Bpifrance and Pemberton joined the company as shareholders. That investment was linked to Juvisé’s acquisition of rights to Ponvory from Johnson & Johnson, a deal that expanded the company’s neurology portfolio. Juvisé said its portfolio is now fully integrated following that acquisition.

Frédéric Mascha, founder and ceo of Juvisé Pharmaceuticals, said the refinancing supports the company’s growth strategy. “This refinancing is a key milestone for Juvisé, strengthening our financial position and enabling us to continue delivering growth with the ambition to acquire and commercialize new essential medicines for patients,” Mascha said. “We are delighted to finalize this operation with our longtime partner Hayfin, whose long-term approach and healthcare capabilities make them an ideal partner to support our continuing development.”

Juvisé focuses on the acquisition and commercialisation of established medicines, with an emphasis on ensuring continued patient access across European markets. The company said the new capital expenditure line is fully dedicated to identifying and executing future acquisition opportunities aligned with this strategy.

Howard Rowe, portfolio manager and co-head of healthcare investing at Hayfin, said the firm views Juvisé as a long-term partner within its healthcare investment portfolio. “We believe the company has demonstrated consistent operational discipline and a strong historic track record of integrating and scaling essential medicines,” Rowe said. “This refinancing strengthens an already solid foundation, and we look forward to continuing our partnership as Juvisé pursues its growth strategy.”

Juvisé said the refinancing reflects confidence in the company’s operational performance and its ability to integrate acquired assets efficiently. The company did not comment on the timing or targets of potential future acquisitions.

Lazard acted as special advisor to Juvisé on the transaction, with Latham & Watkins providing legal counsel. White & Case served as legal advisor to Hayfin.